There are currently 1007 clinical trials in Portland, Oregon looking for participants to engage in research studies. Trials are conducted at various facilities, including Oregon Health & Science University, Oregon Health and Science University /ID# 216891, Providence Portland Medical Center and Providence Saint Vincent Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
NCT05563766
Recruiting
Esophageal cancer, which has a low 5-year overall survival rate (\<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of esophageal cancers. Itraconazole, a widely used anti-fungal medication, effectively inhibits these pathways. In this multi-site phase II trial, the investigators will evaluate the effect of itraconazole as a neoadjuvant therapy added to standard of care chemoradiation and surg... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: VA Portland Health Care System, Portland, OR, Portland, Oregon
Conditions: Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Carcinoma
Register for Updates
Study of Enhanced Programming Stimulation with the Enterra® Therapy System
NCT06560307
Recruiting
The purpose of this research study is to evaluate if an enhanced Enterra device programming strategy will improve symptoms associated with gastroparesis, improve symptoms in a faster amount of time, and improve quality of life measures. Participants in this study will be evaluated for study entry criteria, have an Enterra Therapy System implanted, and be randomly assigned to one of two programming strategies. Participants will answer daily questions about their gastroparesis symptoms on an appl... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
11/13/2024
Locations: Foundation for Surgical Innovation, Portland, Oregon
Conditions: Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
Register for Updates
Study in Parkinson Disease of Exercise
NCT04284436
Recruiting
This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax or 2)80-85% HRmax 4 times per week. The primary objective is to test whether the progression of the signs of Parkinson's disease is attenuated at 12 mon... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
11/12/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Parkinson Disease
Register for Updates
Evaluation of Gixam's Performance in a FIT Negative Population
NCT06612281
Recruiting
In the United States, colorectal cancer ranks second to lung cancer as a cause of cancer death and is the third most commonly occurring cancer in both men and women. Colorectal cancer in most cases develops slowly over a period of years, starting with the growth of precancerous polyps on the colon or rectum wall. The slow development of colorectal cancer makes it possible to detect and prevent it entirely by the removal of the precancerous polyps with colonoscopy. To date, there is no screening... Read More
Gender:
ALL
Ages:
Between 45 years and 85 years
Trial Updated:
11/12/2024
Locations: The Oregon Clinic Gastroenterology-East, Portland, Oregon
Conditions: Colorectal Adenoma, Colorectal Cancer (CRC), Colorectal Cancer (CRC) Screening
Register for Updates
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
NCT04797780
Recruiting
This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Myelodysplastic Syndromes
Register for Updates
The Use of Voice-Based AI in 988 Crisis Counseling
NCT06299384
Recruiting
Effective training requires repeated opportunities for skills practice with performance-based feedback, which is challenging to provide at scale. This research study focuses on developing an AI-based, coding and feedback tool ("LyssnCrisis") for implementation in a nationally utilized crisis call center, training counselors (call-takers) in suicide risk assessment skills, and evaluating LyssnCrisis to improve services and client outcomes. This research study's goal is to maximize the human capac... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: ProtoCall Services, Inc., Portland, Oregon
Conditions: Suicide, Suicide and Self-harm
Register for Updates
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)
NCT04315324
Recruiting
This phase II trial studies how well OBI-3424 works in treating patients with T-cell acute lymphoblastic leukemia that has come back (relapsed) or does not response to treatment (refractory). Drugs used in chemotherapy, such as OBI-3424, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia
Register for Updates
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
NCT04248452
Recruiting
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, wor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Providence Portland Medical Center, Portland, Oregon +1 locations
Conditions: Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
Register for Updates
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211
Recruiting
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the pr... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon +3 locations
Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
North American Prodromal Synucleinopathy Consortium Stage 2
NCT05826457
Recruiting
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Oregon Health Sciences University, Portland, Oregon
Conditions: REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Dementia, Dementia With Lewy Bodies, Multiple System Atrophy, REM Sleep Parasomnias
Register for Updates
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
NCT05682443
Recruiting
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The study is open-label, randomized with active control, multi-center study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: Oregon Health and Science University Knight Cancer Institute - 1621, Portland, Oregon
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
NCT04696731
Recruiting
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647 to define a Phase 2 dose.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/30/2024
Locations: Providence Portland Medical Center, Portland, Oregon
Conditions: Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Register for Updates